Loading clinical trials...
Loading clinical trials...
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Conditions
Interventions
MGCD265
Locations
19
United States
City of Hope
Duarte, California, United States
UC Irvine Medical Center
Orange, California, United States
UC San Diego
San Diego, California, United States
University of Chicago
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Washington University, Alvin J. Siteman Cancer Center
St Louis, Missouri, United States
Start Date
June 1, 2008
Primary Completion Date
September 1, 2018
Completion Date
January 1, 2019
Last Updated
February 12, 2019
NCT05735080
NCT04657068
NCT04900818
NCT05004116
NCT07009886
NCT06440005
Lead Sponsor
Mirati Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions